Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Williams PA, Cates SC, Blitstein JL, Hersey JC, Kosa KM, Long VA, Singh A, Berman D. Evaluating the impact of six Supplemental Nutrition Assistance Program Education interventions on children's at-home diets. Health Educ Behav. 2015 Jun;42(3):329-38. doi: 10.1177/1090198114558589
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Bauman KE, Ennett ST, Foshee VA, Pemberton M, Hicks K. Correlates of participation in a family-directed tobacco and alcohol prevention program for adolescents. Health Educ Behav. 2001 Aug 1;28(4):440-61.
López MV, Rivero E, Serra C, Campo M, Raurich M, Bonfill X. Health survey in health care professionals in Barcelona. Arch Prev Riesgos Laborales. 1998;1(2):55-62.